Incannex Healthcare Inc.IXHL
Key ratios
FCF / Sales
-14564.5%2025
2024
-134501.8%
ROA
-32.2%TTM
2025
-73.5%2024
-57.0%2023
-34.8%
ROE
-381.1%2025
2024
-115.2%2023
-218.4%
Revenue growth
616.7%2025
Recent news
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
Track IXHL in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer